| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Laboratories of Cancer Genetics [C-N. Q., X. G., J. C., B. T. T.], Monoclonal Antibody Production [B. C.], Analytical, Cellular, and Molecular Microscopy [E. J. K., J. H. R.], and Molecular Oncology [C-C. L., L-M. W., G. F. V. W.], Van Andel Research Institute, Grand Rapids, Michigan 49503; Department of Nasopharyngeal Carcinoma, Cancer Center, Sun Yat-sen University of Medical Sciences, Guangzhou 510060, Peoples Republic of China [C-N. Q., X. G., W-Y. M., H-Q. M., M-H. H.]; and Department of Radiology/Radiation Oncology, Baylor College of Medicine, Houston, Texas 77030 [W-Y. M.]
Met tyrosine kinase, the receptor for HGF/SF, is important in various cellular functions, including proliferation, mitogenesis, formation of branching tubules, angiogenesis, and tumor cell invasion and metastasis. However, the role of Met/HGF signaling pathway in nasopharyngeal carcinoma (NPC) has not been evaluated. In this study, we determined the expression profile and clinical correlation of Met/HGF in 66 cases of advanced NPC and the activation mechanisms of Met receptor in five NPC cell lines. Immunofluorescent staining and quantitative image analysis showed that the Met protein was expressed throughout the tumors and normal nasopharyngeal epithelia. Compared with NPC, the Met expression level was higher in columnar nasopharyngeal epithelium but lower in squamous nasopharyngeal epithelium. The normal interstitial stromal tissue expressed the lowest level of Met protein. HGF was detected mainly in the normal interstitial tissue surrounding the tumor. Met protein expression level was inversely correlated with patients survival time; the correlation coefficient was -0.319 (P = 0.009). The mean survival time was 118 months in low Met expression group versus 52 months in high expression group (P = 0.0004). The cumulative 5-year survival rate was 77.68% in low expression group versus 38.24% in high expression group. The clinical stage was also significantly more advanced in high Met expression group. In the multivariate analysis, both clinical stage and Met protein expression level were independent prognostic indicators for patient survival. All of the five NPC cell lines tested did not express hgf mRNA but expressed met mRNA, and tyrosine phosphorylation of Met protein was mainly induced by exogenous HGF stimulation in these cells. No mutation was found in the tyrosine kinase and the juxtamembrane domains of Met receptor in the five NPC cell lines tested. These results indicate that: (a) high Met protein expression level correlates with poorer survival in late-stage NPC and serves as an independent prognostic indicator; and (b) the Met receptor in NPC is activated by its paracrine ligand HGF from the interstitial tissues rather than by an autocrine loop or its activating mutation.
This article has been cited by other articles:
![]() |
D. Wu, L. Chen, W. Liao, Y. Ding, Q. Zhang, Z. Li, and L. Liu Fascin1 expression predicts poor prognosis in patients with nasopharyngeal carcinoma and correlates with tumor invasion Ann. Onc., September 16, 2009; (2009) mdp333v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Knowles, L. P. Stabile, A. M. Egloff, M. E. Rothstein, S. M. Thomas, C. T. Gubish, E. C. Lerner, R. R. Seethala, S. Suzuki, K. M. Quesnelle, et al. HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer Clin. Cancer Res., June 1, 2009; 15(11): 3740 - 3750. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Ginty, S. Adak, A. Can, M. Gerdes, M. Larsen, H. Cline, R. Filkins, Z. Pang, Q. Li, and M. C. Montalto The Relative Distribution of Membranous and Cytoplasmic Met Is a Prognostic Indicator in Stage I and II Colon Cancer Clin. Cancer Res., June 15, 2008; 14(12): 3814 - 3822. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-L. Cheng, W.-G. Huang, Z.-C. Chen, F. Peng, P.-F. Zhang, M.-Y. Li, F. Li, J.-L. Li, C. Li, H. Yi, et al. Identification of Novel Nasopharyngeal Carcinoma Biomarkers by Laser Capture Microdissection and Proteomic Analysis Clin. Cancer Res., January 15, 2008; 14(2): 435 - 445. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Takami, P. Kaposi-Novak, K. Uchida, L. E. Gomez-Quiroz, E. A. Conner, V. M. Factor, and S. S. Thorgeirsson Loss of Hepatocyte Growth Factor/c-Met Signaling Pathway Accelerates Early Stages of N-nitrosodiethylamine Induced Hepatocarcinogenesis Cancer Res., October 15, 2007; 67(20): 9844 - 9851. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Zhao, T. Grabinski, C. Gao, R. S. Skinner, T. Giambernardi, Y. Su, E. Hudson, J. Resau, M. Gross, G. F. Vande Woude, et al. Identification of a Met-Binding Peptide from a Phage Display Library Clin. Cancer Res., October 15, 2007; 13(20): 6049 - 6055. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-B. Song, M.-S. Zeng, W.-T. Liao, L. Zhang, H.-Y. Mo, W.-L. Liu, J.-Y. Shao, Q.-L. Wu, M.-Z. Li, Y.-F. Xia, et al. Bmi-1 Is a Novel Molecular Marker of Nasopharyngeal Carcinoma Progression and Immortalizes Primary Human Nasopharyngeal Epithelial Cells. Cancer Res., June 15, 2006; 66(12): 6225 - 6232. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Mukohara, G. Civiello, I. J. Davis, M. L. Taffaro, J. Christensen, D. E. Fisher, B. E. Johnson, and P. A. Janne Inhibition of the Met Receptor in Mesothelioma Clin. Cancer Res., November 15, 2005; 11(22): 8122 - 8130. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. V. Hay, B. Cao, R. S. Skinner, Y. Su, P. Zhao, M. F. Gustafson, C.-N. Qian, B. T. Teh, B. S. Knudsen, J. H. Resau, et al. Nuclear Imaging of Met-Expressing Human and Canine Cancer Xenografts with Radiolabeled Monoclonal Antibodies (MetSeekTM) Clin. Cancer Res., October 1, 2005; 11(19): 7064s - 7069s. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ren, B. Cao, S. Law, Y. Xie, P. Y. Lee, L. Cheung, Y. Chen, X. Huang, H. M. Chan, P. Zhao, et al. Hepatocyte Growth Factor Promotes Cancer Cell Migration and Angiogenic Factors Expression: A Prognostic Marker of Human Esophageal Squamous Cell Carcinomas Clin. Cancer Res., September 1, 2005; 11(17): 6190 - 6197. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Worden, X. P. Yang, T. L. Lee, L. Bagain, N. T. Yeh, J. G. Cohen, C. Van Waes, and Z. Chen Hepatocyte Growth Factor/Scatter Factor Differentially Regulates Expression of Proangiogenic Factors through Egr-1 in Head and Neck Squamous Cell Carcinoma Cancer Res., August 15, 2005; 65(16): 7071 - 7080. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Akervall, X. Guo, C.-N. Qian, J. Schoumans, B. Leeser, E. Kort, A. Cole, J. Resau, C. Bradford, T. Carey, et al. Genetic and Expression Profiles of Squamous Cell Carcinoma of the Head and Neck Correlate with Cisplatin Sensitivity and Resistance in Cell Lines and Patients Clin. Cancer Res., December 15, 2004; 10(24): 8204 - 8213. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Schag, S. M. Schmidt, M. R. Muller, T. Weinschenk, S. Appel, M. M. Weck, F. Grunebach, S. Stevanovic, H.-G. Rammensee, and P. Brossart Identification of C-Met Oncogene as a Broadly Expressed Tumor-Associated Antigen Recognized by Cytotoxic T-Lymphocytes Clin. Cancer Res., June 1, 2004; 10(11): 3658 - 3666. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Resnick, J. Routhier, T. Konkin, E. Sabo, and V. E. Pricolo Epidermal Growth Factor Receptor, c-MET, {beta}-Catenin, and p53 Expression as Prognostic Indicators in Stage II Colon Cancer: A Tissue Microarray Study Clin. Cancer Res., May 1, 2004; 10(9): 3069 - 3075. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Ginos, G. P. Page, B. S. Michalowicz, K. J. Patel, S. E. Volker, S. E. Pambuccian, F. G. Ondrey, G. L. Adams, and P. M. Gaffney Identification of a Gene Expression Signature Associated with Recurrent Disease in Squamous Cell Carcinoma of the Head and Neck Cancer Res., January 1, 2004; 64(1): 55 - 63. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. V. Hay, B. Cao, R. S. Skinner, L.-M. Wang, Y. Su, J. H. Resau, B. S. Knudsen, M. F. Gustafson, H.-M. Koo, G. F. V. Woude, et al. Radioimmunoscintigraphy of Human Met-Expressing Tumor Xenografts Using Met3, a New Monoclonal Antibody Clin. Cancer Res., September 1, 2003; 9(10): 3839s - 3844s. [Abstract] [Full Text] |
||||
![]() |
H. Takeuchi, A. Bilchik, S. Saha, R. Turner, D. Wiese, M. Tanaka, C. Kuo, H.-J. Wang, and D. S. B. Hoon c-MET Expression Level in Primary Colon Cancer: A Predictor of Tumor Invasion and Lymph Node Metastases Clin. Cancer Res., April 1, 2003; 9(4): 1480 - 1488. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Zeng, L. K. McCauley, and C.-Y. Wang Hepatocyte Growth Factor Inhibits Anoikis by Induction of Activator Protein 1-dependent Cyclooxygenase-2. IMPLICATION IN HEAD AND NECK SQUAMOUS CELL CARCINOMA PROGRESSION J. Biol. Chem., December 13, 2002; 277(51): 50137 - 50142. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Zeng, S. Chen, Z. You, F. Yang, T. E. Carey, D. Saims, and C.-Y. Wang Hepatocyte Growth Factor Inhibits Anoikis in Head and Neck Squamous Cell Carcinoma Cells by Activation of ERK and Akt Signaling Independent of NFkappa B J. Biol. Chem., July 5, 2002; 277(28): 25203 - 25208. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |